Shelly Heimfeld
Overview
Explore the profile of Shelly Heimfeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
6267
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bleakley M, Sehgal A, Seropian S, Biernacki M, Krakow E, Dahlberg A, et al.
J Clin Oncol
. 2022 Jan;
40(11):1174-1185.
PMID: 35007144
Purpose: Graft-versus-host disease (GVHD) causes morbidity and mortality following allogeneic hematopoietic cell transplantation. Naive T cells (T) cause severe GVHD in murine models. We evaluated chronic GVHD (cGVHD) and other...
2.
Bai T, Li J, Sinclair A, Imren S, Merriam F, Sun F, et al.
Nat Med
. 2019 Oct;
25(10):1566-1575.
PMID: 31591594
The ability to expand hematopoietic stem and progenitor cells (HSPCs) ex vivo is critical to fully realize the potential of HSPC-based therapies. In particular, the application of clinically effective therapies,...
3.
Sullivan K, Goldmuntz E, Keyes-Elstein L, McSweeney P, Pinckney A, Welch B, et al.
N Engl J Med
. 2018 Jan;
378(1):35-47.
PMID: 29298160
Background: Despite current therapies, diffuse cutaneous systemic sclerosis (scleroderma) often has a devastating outcome. We compared myeloablative CD34+ selected autologous hematopoietic stem-cell transplantation with immunosuppression by means of 12 monthly...
4.
Lee S, Olsen P, Lee D, Kenoyer A, Budde L, OSteen S, et al.
J Immunother
. 2017 Nov;
41(1):19-31.
PMID: 29176334
Chimeric antigen receptor (CAR)-based adoptive T-cell therapy is a highly promising treatment for lymphoid malignancies, and CD20 is an ideal target antigen. We previously developed a lentiviral construct encoding a...
5.
Turtle C, Hay K, Hanafi L, Li D, Cherian S, Chen X, et al.
J Clin Oncol
. 2017 Jul;
35(26):3010-3020.
PMID: 28715249
Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib. Methods Twenty-four...
6.
Keever-Taylor C, Heimfeld S, Steinmiller K, Nash R, Sullivan K, Czarniecki C, et al.
Biol Blood Marrow Transplant
. 2017 Jun;
23(9):1463-1472.
PMID: 28602891
To ensure comparable grafts for autologous hematopoietic cell transplantation (HCT) in the National Institute of Allergy and Infectious Diseases-sponsored Investigational New Drug protocols for multiple sclerosis (HALT-MS) and systemic sclerosis...
7.
Milano F, Merriam F, Nicoud I, Li J, Gooley T, Heimfeld S, et al.
Stem Cells Transl Med
. 2017 Feb;
6(2):566-575.
PMID: 28191773
The hematopoietic syndrome of acute radiation syndrome (h-ARS) is characterized by severe bone marrow aplasia, resulting in a significant risk for bleeding, infections, and death. To date, clinical management of...
8.
Li J, Nicoud I, Blake J, Oliver D, Cox E, Heimfeld S, et al.
Biol Blood Marrow Transplant
. 2016 Dec;
23(3):412-419.
PMID: 28007666
Cord blood transplantation (CBT) recipients are at increased risk for delayed engraftment and primary graft failure, complications that are often indistinguishable early post-transplantation. Current assays fail to accurately identify recipients...
9.
Adair J, Waters T, Haworth K, Kubek S, Trobridge G, Hocum J, et al.
Nat Commun
. 2016 Oct;
7:13173.
PMID: 27762266
Haematopoietic stem cell (HSC) gene therapy has demonstrated potential to treat many diseases. However, current state of the art requires sophisticated ex vivo gene transfer in a dedicated Good Manufacturing...
10.
Turtle C, Hanafi L, Berger C, Hudecek M, Pender B, Robinson E, et al.
Sci Transl Med
. 2016 Sep;
8(355):355ra116.
PMID: 27605551
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in...